Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8700
Nov 17 • 12:19 PM ET Dollar change+0.0540 Percentage change(6.62%)
Nov 16, 8:37 AMIN8bio reports updated INB-200/400 glioblastoma data showing 20.9-month median overall survival and 50% two-year survival among repeat-dose patients.
Index
-
Market Cap
9.40M
Enterprise Value
-1.82M
Income
-19.41M
Sales
0.00M
Book/sh
1.44
Cash/sh
1.29
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
17
IPO
Jul 30, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.61
P/C
0.67
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.78
Current Ratio
5.78
Debt/Eq
0.19
LT Debt/Eq
0.13
Option/Short
No / Yes
EPS (ttm)
-1.25
EPS next Y
-0.83
EPS next Q
-0.21
EPS this Y
78.27%
EPS next Y
13.47%
EPS next 5Y
50.76%
EPS past 3/5Y
52.25% 22.63%
Sales past 3/5Y
- -
EPS Y/Y TTM
81.16%
Sales Y/Y TTM
-
EPS Q/Q
72.24%
Sales Q/Q
-
Insider Own
7.35%
Insider Trans
0.00%
Inst Own
34.99%
Inst Trans
-5.41%
ROA
-109.44%
ROE
-141.83%
ROIC
-120.78%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-6.14%
SMA50
-20.22%
SMA200
-36.68%
Trades
Shs Outstand
10.81M
Shs Float
10.01M
52W High
2.73 -68.13%
52W Low
0.72 20.23%
Volatility
12.00% 9.61%
ATR (14)
0.10
RSI (14)
40.70
Beta
0.25
Rel Volume
1.33
Avg Volume
120.20K
Volume
74,018
Perf Week
-3.33%
Perf Month
-20.18%
Perf Quarter
-27.50%
Perf Half Y
-40.00%
Perf YTD
-62.82%
Perf Year
-45.28%
Perf 3Y
-96.81%
Perf 5Y
-99.64%
Perf 10Y
-
Prev Close
0.82
Price
0.87
Change %
6.62%
Consensus
Strong Buy
Avg. Price Target
$7.50
Implied Upside
+762.1%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 18, 2024Initiated
LLaidlaw
Buy$7.50+762.1%
Aug 30, 2022Initiated
HH.C. Wainwright
Buy$14+1,509.2%
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Co-FounderMr. Tai-Wei Ho
President & COODr. Kate Rochlin Ph.D.
CFO & SecretaryMr. Patrick McCall CPA
Executive VPDr. Lawrence S. Lamb Ph.D.
Senior Vice President of Research & DevelopmentDr. Oxana Polyakova Ph.D.